FULC · Fulcrum Therapeutics Inc
United States · RS rating 30 · As of 2026-10-14
| Price | 3.67 USD |
|---|---|
| 1-day change | -0.3% |
| RS rating (overall / 1M / 3M / 12M) | 30 / 47 / 80 / 11 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 18 / 13 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +74.9% |
| Market cap (USD) | $538.1M |